HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Suppl Data Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Faught, E. Articles by Leppik, I. E. Search for Related Content PubMed PubMed Citation Articles by Faught, E. Articles by Leppik, I. E. Related Collections Antiepileptic drugs Partial seizures

Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures

From the University of Alabama School of Medicine (Dr. Faught), Birmingham; Tallahassee Neurology Clinic (Dr. Ayala), FL; Comprehensive Epilepsy Care Center (Dr. Montouris), St. Louis, MO; and the Minnesota Comprehensive Epilepsy Program (MINCEP) Epilepsy Care and the University of Minnesota (Dr. Leppik), Minneapolis.

Address correspondence and reprint requests to Dr. E. Faught, UAB Epilepsy Center, Civitan International Research Center 312, 1719 Sixth Avenue South, Birmingham, AL 35294-0021.

Background:— Zonisamide is a sulfonamide antiepilepsy drug with sodium and calcium channel–blocking actions. Experience in Japan and a previous European double-blind study have demonstrated its efficacy against partial-onset seizures.

Methods:— A randomized, double-blind, placebo-controlled trial enrolling 203 patients was conducted at 20 United States sites to assess zonisamide efficacy and dose response as adjunctive therapy for refractory partial-onset seizures. Zonisamide dosages were elevated by 100 mg/d each week. The study design allowed parallel comparisons with placebo for three dosages and a final crossover to 400 mg/d of zonisamide for all patients. The primary efficacy comparison was change in seizure frequency from a 4-week placebo baseline to weeks 8 through 12 on blinded therapy.

Results:— At 400 mg/d, zonisamide reduced the median frequency of all seizures by 40.5% from baseline, compared with a 9% reduction (p = 0.0009) with placebo treatment, and produced a 50% seizure reduction (responder rate) in 42% of patients. A dosage of 100 mg/d produced a 20.5% reduction in median seizure frequency (p = 0.038 compared with placebo) and a dosage of 200 mg/d produced a 24.7% reduction in median seizure frequency (p = 0.004 compared with placebo). Dropouts from adverse events (10%) did not differ from placebo (8.2%, NS). The only adverse event differing significantly from placebo was weight loss, though somnolence, anorexia, and ataxia were slightly more common with zonisamide treatment. Serum zonisamide concentrations rose with increasing dose.

Conclusion:— Zonisamide is effective and well tolerated as an adjunctive agent for refractory partial-onset seizures. The minimal effective dosage was 100 mg/d, but 400 mg/d was the most effective dosage.

This article has been cited by other articles:

				R. J. Porter, A. Partiot, R. Sachdeo, V. Nohria, W. M. Alves, and on behalf of the 205 Study Group Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures Neurology, April 10, 2007; 68(15): 1197 - 1204. [Abstract] [Full Text] [PDF]

				D. E. Mandelbaum, M. Bunch, S. L. Kugler, A. Venkatasubramanian, and J. B. Wollack Broad-Spectrum Efficacy of Zonisamide at 12 Months in Children With Intractable Epilepsy J Child Neurol, July 1, 2005; 20(7): 594 - 597. [Abstract] [PDF]

				H. L. Kim, J. Aldridge, and J. M. Rho Clinical Experience With Zonisamide Monotherapy and Adjunctive Therapy in Children With Epilepsy at a Tertiary Care Referral Center J Child Neurol, March 1, 2005; 20(3): 212 - 219. [Abstract] [PDF]

				C. W. Dewey, R. Guiliano, D. M. Boothe, J. M. Berg, G. D. Kortz, R. J. Joseph, and S. C. Budsberg Zonisamide Therapy for Refractory Idiopathic Epilepsy in Dogs J. Am. Anim. Hosp. Assoc., July 1, 2004; 40(4): 285 - 291. [Abstract] [Full Text] [PDF]

				J. A. French, A. M. Kanner, J. Bautista, B. Abou-Khalil, T. Browne, C. L. Harden, W. H. Theodore, C. Bazil, J. Stern, S. C. Schachter, et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society Neurology, April 27, 2004; 62(8): 1261 - 1273. [Abstract] [Full Text] [PDF]

				S. M. LaRoche and S. L. Helmers The New Antiepileptic Drugs: Scientific Review JAMA, February 4, 2004; 291(5): 605 - 614. [Abstract] [Full Text] [PDF]

				D. K. Nguyen and S. S. Spencer Recent Advances in the Treatment of Epilepsy Arch Neurol, July 1, 2003; 60(7): 929 - 935. [Full Text] [PDF]

				T. A. Glauser Integrating clinical trial data into clinical practice Neurology, June 25, 2002; 58(12_suppl_7): S6 - S12. [Full Text]

				I. E. Leppik Three New Drugs for Epilepsy: Levetiracetam, Oxcarbazepine, and Zonisamide J Child Neurol, January 1, 2002; 17(1_suppl): S53 - S57. [Abstract] [PDF]

Correspondence: